CJC-1295 / Ipamorelin

Name: CJC-1295 / Ipamorelin
Availability: InStock

5mg / 5mg vial

A pre-mixed blend of CJC-1295 (without DAC) and Ipamorelin, each at 5mg per vial. The two compounds act on complementary axes - GHRH and ghrelin/GHS-R1a - producing a dual-pathway synergistic GH pulse significantly larger than either compound alone, with minimal cortisol or prolactin impact.

Checking availability…

Researched for

Synergistic GH pulse amplitude greater than either compound alone
Improved body composition (reduced adipose, increased lean mass)
Recovery and collagen turnover via downstream IGF-1 elevation
Improved slow-wave sleep architecture in research subjects
Improved lipid panel and insulin-sensitivity markers (GH-deficient studies)
Restored youthful GH pulsatility without HGH-style axis suppression

Mechanism of action

CJC-1295 (no DAC) is a stabilised GHRH analogue that binds pituitary GHRH receptors to stimulate GH synthesis. Ipamorelin is a selective pentapeptide ghrelin/GHS-R1a agonist that triggers acute GH pulses with high receptor specificity.

Research protocol

Common research protocols use 100–200mcg CJC-1295 (no DAC) plus 100–300mcg Ipamorelin per injection, once daily 30–60 minutes pre-sleep to align with the natural nocturnal GH pulse. Cycles typically run 8–12 weeks on / 4 weeks off.

Half-life

CJC-1295 (no DAC): approx. 30 minutes. Ipamorelin: approx. 2 hours.

Reconstitution

Standard: reconstitute each 2mg vial with 2mL bacteriostatic water for a 1,000mcg/mL concentration. For combined 10mg blend vials, 3–5mL BW is typical. Swirl gently.

Storage

Lyophilised: 2–8°C (stable up to 24 months frozen). Reconstituted: 2–8°C, protect from light and heat, use within 28–30 days.

Research considerations

• Mild water retention or peripheral oedema can occur, particularly at higher doses - typically dose-dependent.
• Injection-site reactions (redness, itching, transient swelling) are common with SC peptide administration.
• Chronic IGF-1 elevation should be monitored; sustained supraphysiological dosing carries acromegaly-style risk.

Other peptides